{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:13Z","timestamp":1789587013480,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Diabetes & Endocrinology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/s2213-8587(26)00126-9","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T21:34:14Z","timestamp":1780868054000},"page":"649-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of once-weekly cagrilintide\u2013semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study"],"prefix":"10.1016","volume":"14","author":[{"given":"Vanita R","family":"Aroda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Buzzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine-Mathilde","family":"Dalskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay B","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Hughes","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Videmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torquil","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2213-8587(26)00126-9_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","article-title":"11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050","volume":"14","author":"Genitsaridi","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00126-9_bib2","first-page":"S27","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00126-9_bib3","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00126-9_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105488","article-title":"Overnutrition, hyperinsulinemia and ectopic fat: it is time for a paradigm shift in the management of type 2 diabetes","volume":"25","author":"Janssen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/S2213-8587(26)00126-9_bib5","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2337\/db24-0083","article-title":"Effect of weight loss on skeletal muscle bioactive lipids in people with obesity and type 2 diabetes","volume":"73","author":"Petersen","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/S2213-8587(26)00126-9_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00126-9_bib7","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20132026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00126-9_bib8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00126-9_bib11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00126-9_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00126-9_bib13","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00126-9_bib14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/S2213-8587(26)00126-9_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s42255-026-01465-4","article-title":"The story of amylin: from physiology to therapy","volume":"8","author":"Secher","year":"2026","journal-title":"Nat Metab"},{"key":"10.1016\/S2213-8587(26)00126-9_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00126-9_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide\u2013semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00126-9_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)01022-6","article-title":"Cagrilintide\u2013semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00126-9_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/S2213-8587(26)00126-9_bib21","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.2337\/dci21-0034","article-title":"Consensus report: definition and interpretation of remission in type 2 diabetes","volume":"44","author":"Riddle","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/S2213-8587(26)00126-9_bib22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bimj.201000239","article-title":"Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests","volume":"53","author":"Bretz","year":"2011","journal-title":"Biom J"},{"key":"10.1016\/S2213-8587(26)00126-9_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2021.06.024","article-title":"Primary and secondary outcome reporting in randomized trials: JACC state-of-the-art review","volume":"78","author":"Pocock","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S2213-8587(26)00126-9_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41366-020-00733-x","article-title":"Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data","volume":"45","author":"Wharton","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/S2213-8587(26)00126-9_bib25","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.13804","article-title":"Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example","volume":"21","author":"Aroda","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00126-9_bib26","first-page":"S132","article-title":"6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00126-9_bib27","first-page":"1","article-title":"Assessing cardiovascular safety and outcomes with the combination of cagrilintide and semaglutide (CagriSema): REDEFINE 3 randomised clinical trial baseline characteristics and methods","volume":"19","author":"Cavender","year":"2026","journal-title":"Obes Facts"},{"key":"10.1016\/S2213-8587(26)00126-9_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00126-9_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00126-9_bib30","article-title":"Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study","volume":"59","author":"Fadini","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/S2213-8587(26)00126-9_bib31","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad056","article-title":"Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1)","volume":"7","author":"Lee","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/S2213-8587(26)00126-9_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00126-9_bib33","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S2213-8587(26)00126-9_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"}],"container-title":["The Lancet Diabetes & Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858726001269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858726001269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:55:31Z","timestamp":1785963331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858726001269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2213858726001269"],"URL":"https:\/\/doi.org\/10.1016\/s2213-8587(26)00126-9","relation":{},"ISSN":["2213-8587"],"issn-type":[{"value":"2213-8587","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of once-weekly cagrilintide\u2013semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Diabetes & Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(26)00126-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(26)00129-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}